BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 10, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	49	19	86	602	569	1,126
Market Cap Growth	99.94%	-78.51%	-85.65%	5.82%	-49.47%	327.27%
Enterprise Value	119	83	96	462	317	895
Last Close Price	2.13	5.98	47.20	343.68	325.28	739.20
PS Ratio	21.26	8.19	62.58	1605.17	-	-
PB Ratio	-	-0.20	-1.53	7.84	2.57	5.45
P/TBV Ratio	-	-	-	7.84	2.57	5.45
EV/Sales Ratio	158.29	36.69	69.82	1233.33	-	-
Debt / Equity Ratio	-1.23	-1.11	-1.79	1.22	0.01	0.01
Asset Turnover	0.02	0.04	0.01	0.00	-	-
Inventory Turnover	0.97	1.61	0.63	-	-	-
Quick Ratio	0.96	1.35	2.40	5.90	13.98	18.00
Current Ratio	1.18	1.68	2.65	6.17	14.21	18.33
Return on Equity (ROE)	-	-	-1766.94%	-111.08%	-49.93%	-70.35%
Return on Assets (ROA)	-67.31%	-72.30%	-74.95%	-44.81%	-29.10%	-40.13%
Return on Capital (ROIC)	-158.82%	-148.97%	-97.39%	-50.73%	-31.02%	-43.59%
Return on Capital Employed (ROCE)	-721.90%	-402.40%	-361.00%	-92.30%	-48.00%	-39.50%
Earnings Yield	-148.52%	-321.18%	-207.35%	-27.54%	-18.80%	-7.30%
FCF Yield	-126.76%	-388.15%	-179.52%	-22.51%	-14.52%	-5.92%
Buyback Yield / Dilution	-235.79%	-39.21%	-4.00%	-6.23%	-21.63%	-33.11%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q